Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Varying VRd regimens in real-world patients

Surbhi Sidana • 14 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Dexamethasone Lenalidomide

Surbhi Sidana, MBBS Mayo Clinic, Rochester, MN, presents results on investigations into different regiments of bortezomib, lenalidomide, dexamethasone (VRd) and their efficacy and toxicity in real-world patients at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Surbhi Sidana

1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals